[1]史建华,刘瑞强,尹茂轩,等.生地黄制剂对前列腺癌晚期患者血清标志物的改善作用与安全性研究*[J].陕西中医,2019,(8):1073-1076.
　SHI Jianhua,LIU Ruiqiang,YIN Maoxuan,et al.Effect and safety of Shengdihuang decoction on serum markers of patients with advanced prostate cancer[J].,2019,(8):1073-1076.
点击复制

生地黄制剂对前列腺癌晚期患者血清标志物的改善作用与安全性研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
1073-1076
栏目:
临床研究
出版日期:
2019-08-05

文章信息/Info

Title:
Effect and safety of Shengdihuang decoction on serum markers of patients with advanced prostate cancer
文章编号:
DOI:10.3969/j.issn.1000-7369.2019.08.024
作者:
史建华1; 刘瑞强1; 尹茂轩1; 杨帮东1 ; 李冠军2
1.河南省濮阳市人民医院泌尿外科(濮阳 457000);2.南阳医学高等专科学校第一附属医院泌尿外科(南阳 473000)
Author(s):
SHI Jianhua; LIU Ruiqiang; YIN Maoxuan; et al.
Department of Urology Surgical,Puyang People Undefineds Hospital(Puyang 457000)
关键词:
前列腺癌; 晚期; 生地黄复方制剂; 前列腺特异抗原; 游离前列腺特异性抗原; 生活质量
Keywords:
Key words Prostate cancer; Later period;  Shengdihuang decoction; Prostate-specific antigen; Free prostate-specific antigen; Quality of life
分类号:
R737.25
文献标志码:
A
摘要:
摘 要 目的：观察生地黄复方制剂应用于前列腺癌晚期患者治疗中的疗效、安全性及对患者血清标志物的改善作用。方法：选取96例前列腺癌晚期患者作为入选资料，将入选患者均分为对照组与观察组，对照组采取常规治疗，观察组在对照组的基础上应用生地黄复方制剂治疗，两组均以6个月为1个疗程。治疗1个疗程后，评估两组临床疗效，同时观察组治疗前、后两组患者血清标志物表达水平、免疫指标、生活质量、情绪状态及中医证候积分的改善情况，统计两组患者治疗期间不良反应发生情况。结果：观察组整体疗效较对照组理想（P＜0.05）；治疗后，两组患者PSA、f-PSA、Hb均较前改善（P＜0.05），观察组PSA、f-PSA、Hb均优于对照组（P＜0.05）；治疗后，观察组CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞均较治疗前改善（P＜0.05），观察组T细胞亚群与NK细胞均优于对照组（P＜0.05）；治疗后，两组患者生活质量、中医证候与 I-PSS均较前改善（P＜0.05），观察组各项指标均优于对照组（P＜0.05）。对照组不良反应发生率为29.17%，观察组不良反应发生率为10.42%，观察组不良反应发生率低于对照组（P＜0.05）。结论：生地黄复方制剂可提高前列腺癌晚期患者临床疗效，降低血清标志物表达水平，改善患者生存质量，并可减少不良反应发生率具有用药安全性高的优势。
Abstract:
Abstract Objective：To investigate the effect and safety of Shengdihuang decoction on serum markers of patients with advanced prostate cancer. Methods:A total of 96 patients with advanced prostate cancer were admitted. All patients were divided into control group and observation group. The control group was treated with traditional treatment,and the observation group was treated with the compound preparation of rehmannia glutinosa on the basis of the control group. Both groups were treated for 6 months. The expression of serum marker levels,immune index,quality of life,emotional state,and improvement of TCM syndrome scores were compared between 2 groups. The incidence of adverse reactions were recorded during the treatment. Results:The overall efficacy of the observation group was better than that of the control group (P＜0.05). The PSA,f-PSA,Hb were improved after treatment in 2 groups (all P＜0.05),and the observation group was superior to the control group (P＜0.05). After treatment,the CD3+,CD4+,CD4+/CD8+,NK cells of the control group were lower than those before treatment (all P＜0.05),and the CD3+,CD4+,CD4+/CD8+,NK cells of the observation group were higher than those before treatment (all P＜0.05). The T-cell subsets and NK cells of the observation group were superior to the control group (all P＜0.05). The quality of life,TCM syndrome and I-PSS were improved after treatment in 2 groups (all P＜0.05),and the observation group were superior to the control group (P＜0.05). The incidence of adverse reactions was 29.17% in the control group,and was 10.42% in the observation group,respectively (P＜0.05). Conclusion：The efficacy of Shengdihuang compound rehmannia in the treatment of patients with advanced prostate cancer is well,and it can reduce the expression level of serum markers,improve the quality of life,reduce the incidence of adverse reactions,and obtain high safety of medication.

参考文献/References:

[1] 陈 磊,冯懿赓,郁 超,等.芪凌方联合岩舒注射液治疗晚期前列腺癌的临床疗效[J].辽宁中医杂志,2017,44(7):1451-1453.
[2] 张立国,张金存,王 磊,等.扶正抑瘤法对晚期前列腺癌患者生存期的影响及效果分析[J].中华中医药学刊,2016,34(11):2814-2816.
[3] 郑 伟,薛超辉,雷 毅,等.腹腔镜下根治术对早期前列腺癌近期效果及尿流动力学远期影响[J].陕西医学杂志,2017,46(9):1202-1205.
[4] Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
[5] 骆华春,傅志超,冯 静,等.同期调强放疗联合内分泌治疗对局部晚期前列腺癌乏力症状的影响[J].肿瘤防治研究,2016,43(6):502-507.
[6] 曹宏文,冯懿赓,周智恒,等.周氏芪凌汤治疗晚期前列腺癌的临床观察[J].中国男科学杂志,2015,29(6):59-62.
[7] 那彦群.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2006:62-65.
[8] 吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004:1145-1146.
[9] 王建平,陈仲庚,林文娟,等.中国癌症病人生活质量的测定-EORTC QLQ C30在中国的试用[J].心理学报,2000,32(5):438-442.
[10] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)\[S\].北京:中国医药出版社,2002:346-346.
[11] Duffaud F,Therasse P.New guidelines to evaluatethe response to treatment in solid tumors [J].Bull Caner,2000,87(12):881-886.
[12] 杨 柱,唐东昕,郭 斌,等.刘尚义治疗肿瘤用药经验数据挖掘分析[J].中医杂志,2016,57(19):1641-1645.
[13] 刘春雷,崔 涛,陈黎黎,等.内分泌联合维生素D应用于晚期前列腺癌的治疗探讨[J].中华肿瘤防治杂志,2016,23(S1):202-203.
[14] 李明林.健脾益肾方对前列腺癌患者手术去势后性激素、PSA的影响研究[J].陕西中医,2018,39(3):354-357.
[15] 司富春,杜超飞.前列腺癌的中医证候和方药规律分析[J].中华中医药杂志,2015,2(6):581-585.

相似文献/References:

[1]苏剑飞,牟睿宇,刘筱迪,等.贾英杰教授从“脾”论治前列腺癌[J].陕西中医,2023,(5):636.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.023]
　SU Jianfei,MOU Ruiyu,LIU Xiaodi,et al.Professor JIA Yingjie's thoughts on treating prostate cancer from the perspective of “spleen”[J].,2023,(8):636.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.023]

备注/Memo

备注/Memo:
*河南省医学科技攻关计划项目(201404163)
更新日期/Last Update: 2019-08-15